Australian clinical-stage drug development company Syntara has announced a new Phase 2 trial evaluating the combination treatment of its SNT-5505 with chemotherapy in patients with low and intermediate-risk myelodysplastic syndrome. …
Australian company launches new blood cancer trial of lead candidate
February 15, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Nyrada advances toward Phase 2a trial of cardioprotective candidate
November 18, 2025 - - Australian Biotech -
We know they're planning something on these issues, because they told us
November 18, 2025 - - Latest News -
The need to honour a strong history while ensuring the future is guided by the 'good guys'
November 17, 2025 - - Latest News -
BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia
November 17, 2025 - - Latest News -
Syntara secures positive European opinion for orphan designation of amsulostat in myelofibrosis
November 17, 2025 - - Australian Biotech -
Mesoblast appoints Chief Financial Officer as it evolves into fully integrated commercial organisation
November 17, 2025 - - Australian Biotech -
Argent BioPharma secures significant financing facility to support strategic expansion
November 17, 2025 - - Australian Biotech